• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22336 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2023     National Institute for Health and Care Excellence (NICE) Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934
2010     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
2010     National Institute for Health and Care Excellence (NICE) Interspinous distraction procedures for lumbar spinal stenosis causing neurogenic claudication
2012     National Institute for Health and Care Excellence (NICE) Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 268
2021     National Institute for Health and Care Excellence (NICE) Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal). NICE technology appraisal guidance 675
2023     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2007     National Institute for Health and Care Excellence (NICE) Feverish illness in children: assessment and initial management in children younger than 5 years
2010     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of rheumatoid arthritis
2010     National Institute for Health and Care Excellence (NICE) Strategies to prevent unintentional injuries among under-15s
2012     National Institute for Health and Care Excellence (NICE) Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269
2021     National Institute for Health and Care Excellence (NICE) Filgotinib for treating moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 676
2023     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2006     National Institute for Health and Care Excellence (NICE) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2007     National Institute for Health and Care Excellence (NICE) Secondary prevention in primary and secondary care for patients following a myocardial infarction
2010     National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
2010     National Institute for Health and Care Excellence (NICE) Preventing unintentional road injuries among under-15s - road design
2012     National Institute for Health and Care Excellence (NICE) Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 270
2021     National Institute for Health and Care Excellence (NICE) Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 677
2006     National Institute for Health and Care Excellence (NICE) Laparoscopic surgery for colorectal cancer: review of NICE technology appraisal 17
2007     National Institute for Health and Care Excellence (NICE) Cardiac resynchronisation therapy for the treatment of heart failure
2010     National Institute for Health and Care Excellence (NICE) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
2010     National Institute for Health and Care Excellence (NICE) Preventing unintentional injuries in the home among children and young people aged under 15: providing safety equipment and home risk assessments
2021     National Institute for Health and Care Excellence (NICE) Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 678
2006     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
2007     National Institute for Health and Care Excellence (NICE) Therapeutic sialendoscopy
2010     National Institute for Health and Care Excellence (NICE) Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
2010     National Institute for Health and Care Excellence (NICE) Promoting the quality of life of looked-after children and young people
2021     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 679
2006     National Institute for Health and Care Excellence (NICE) Thoracoscopically assisted oesophagectomy
2007     National Institute for Health and Care Excellence (NICE) Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery
2010     National Institute for Health and Care Excellence (NICE) Dronedarone for the treatment of non-permanent atrial fibrillation
2010     National Institute for Health and Care Excellence (NICE) Dietary interventions and physical activity interventions for weight management before, during and after pregnancy
2021     National Institute for Health and Care Excellence (NICE) Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. NICE technology appraisal guidance 680
2006     National Institute for Health and Care Excellence (NICE) Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease)
2007     National Institute for Health and Care Excellence (NICE) Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium
2010     National Institute for Health and Care Excellence (NICE) Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
2010     National Institute for Health and Care Excellence (NICE) How to stop smoking in pregnancy and following childbirth
2021     National Institute for Health and Care Excellence (NICE) Baricitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 681
2007     National Institute for Health and Care Excellence (NICE) Workplace health promotion: how to help employees to stop smoking
2010     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
2010     National Institute for Health and Care Excellence (NICE) Prevention of cardiovascular disease at the population level
2021     National Institute for Health and Care Excellence (NICE) Erenumab for preventing migraine. NICE technology appraisal guidance 682
2007     National Institute for Health and Care Excellence (NICE) Injectable bulking agents for faecal incontinence
2010     National Institute for Health and Care Excellence (NICE) Capecitabine for the treatment of advanced gastric cancer
2010     National Institute for Health and Care Excellence (NICE) Alcohol-use disorders - preventing the development of hazardous and harmful drinking
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 683
2007     National Institute for Health and Care Excellence (NICE) Radiofrequency-assisted liver resection
2010     National Institute for Health and Care Excellence (NICE) Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal)
2010     National Institute for Health and Care Excellence (NICE) School-based interventions to prevent the uptake of smoking among children
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. NICE technology appraisal guidance 684
2007     National Institute for Health and Care Excellence (NICE) Laparoscopic nephrolithotomy and pyelolithotomy
2010     National Institute for Health and Care Excellence (NICE) Pemetrexed for the maintenance treatment of non-small-cell lung cancer
2010     National Institute for Health and Care Excellence (NICE) Transperineal template biopsy of the prostate
2021     National Institute for Health and Care Excellence (NICE) Anakinra for treating Still's disease. NICE technology appraisal guidance 685
2007     National Institute for Health and Care Excellence (NICE) Arthroscopic femoro-acetabular surgery for hip impingement syndrome
2010     National Institute for Health and Care Excellence (NICE) Human growth hormone (somatropin) for the treatment of growth failure in children
2010     National Institute for Health and Care Excellence (NICE) Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome
2021     National Institute for Health and Care Excellence (NICE) Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 686
2007     National Institute for Health and Care Excellence (NICE) Microwave ablation of hepatocellular carcinoma
2010     National Institute for Health and Care Excellence (NICE) Sorafenib for the treatment of advanced hepatocellular carcinoma
2010     National Institute for Health and Care Excellence (NICE) Minimally invasive total hip replacement
2021     National Institute for Health and Care Excellence (NICE) Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 687
2007     National Institute for Health and Care Excellence (NICE) Mesh sacrocolpopexy for vaginal vault prolapse
2010     National Institute for Health and Care Excellence (NICE) Infliximab (review) and adalimumab for the treatment of Crohn's disease
2010     National Institute for Health and Care Excellence (NICE) Insertion of metal rib reinforcements to stabilise a flail chest wall
2021     National Institute for Health and Care Excellence (NICE) Selective internal radiation therapies for treating hepatocellular carcinoma. NICE technology appraisal guidance 688
2007     National Institute for Health and Care Excellence (NICE) Lower limb deep vein valve reconstruction for chronic deep venous incompetence
2010     National Institute for Health and Care Excellence (NICE) Trabectedin for the treatment of advanced soft tissue sarcoma
2010     National Institute for Health and Care Excellence (NICE) Endoscopic submucosal dissection of gastric lesions
2021     National Institute for Health and Care Excellence (NICE) Acalabrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 689
2010     National Institute for Health and Care Excellence (NICE) Certolizumab pegol for the treatment of rheumatoid arthritis
2010     National Institute for Health and Care Excellence (NICE) Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions
2021     National Institute for Health and Care Excellence (NICE) Avelumab for untreated metastatic Merkel cell carcinoma. NICE technology appraisal guidance 691
2009     National Institute for Health and Care Excellence (NICE) Topotecan for the treatment of relapsed small-cell lung cancer
2010     National Institute for Health and Care Excellence (NICE) Phototherapeutic laser keratectomy for corneal surface irregularities
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 692
2009     National Institute for Health and Care Excellence (NICE) Topotecan for the treatment of recurrent and stage IVB cervical cancer
2010     National Institute for Health and Care Excellence (NICE) Percutaneous intradiscal laser ablation in the lumbar spine
2021     National Institute for Health and Care Excellence (NICE) Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 693
2009     National Institute for Health and Care Excellence (NICE) Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
2010     National Institute for Health and Care Excellence (NICE) Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer
2021     National Institute for Health and Care Excellence (NICE) Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 694
2009     National Institute for Health and Care Excellence (NICE) Ustekinumab for the treatment of adults with moderate to severe psoriasis
2010     National Institute for Health and Care Excellence (NICE) Endoscopic submucosal dissection (ESD) of oesophageal dysplasia and neoplasia
2021     National Institute for Health and Care Excellence (NICE) Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma. NICE technology appraisal guidance 695
2009     National Institute for Health and Care Excellence (NICE) Pemetrexed for the first-line treatment of non-small-cell lung cancer
2010     National Institute for Health and Care Excellence (NICE) Shoulder resurfacing arthroplasty
2021     National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 696
2009     National Institute for Health and Care Excellence (NICE) Sunitinib for the treatment of gastrointestinal stromal tumours
2010     National Institute for Health and Care Excellence (NICE) Percutaneous radiofrequency ablation of renal cancer
2021     National Institute for Health and Care Excellence (NICE) Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban. NICE technology appraisal guidance 697
2009     National Institute for Health and Care Excellence (NICE) Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
2010     National Institute for Health and Care Excellence (NICE) Percutaneous mitral valve annuloplasty
2021     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 698
2009     National Institute for Health and Care Excellence (NICE) Alitretinoin for the treatment of severe chronic hand eczema
2010     National Institute for Health and Care Excellence (NICE) Stapled transanal rectal resection for obstructed defaecation syndrome
2021     National Institute for Health and Care Excellence (NICE) Ofatumumab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 699
2009     National Institute for Health and Care Excellence (NICE) Cetuximab for the first-line treatment of metastatic colorectal cancer
2010     National Institute for Health and Care Excellence (NICE) Photodynamic therapy for Barrett's oesophagus